Perspective Therapeutics Stock Performance
| CATX Stock | 4.70 0.32 6.37% |
Perspective Therapeutics holds a performance score of 12 on a scale of zero to a hundred. The company holds a Beta of 1.32, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Perspective Therapeutics will likely underperform. Use Perspective Therapeutics value at risk, as well as the relationship between the kurtosis and price action indicator , to analyze future returns on Perspective Therapeutics.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Perspective Therapeutics are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unfluctuating basic indicators, Perspective Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (6.37) | Five Day Return (0.42) | Year To Date Return 68.46 | Ten Year Return (31.88) | All Time Return (90.78) |
Last Split Factor 1:10 | Last Split Date 2024-06-17 |
1 | Acquisition by Johan Spoor of 6600 shares of Perspective Therapeutics at 3.8 subject to Rule 16b-3 | 11/21/2025 |
2 | Trading Recap How Perspective Therapeutics Inc. stock valuations compare to rivals - 2025 Support Resistance AI Powered Market Trend Analysis - | 12/19/2025 |
3 | Market Review Will Perspective Therapeutics Inc stock continue upward momentum - Trend Reversal Risk Adjusted Buy and Sell Alerts - moha.gov.vn | 12/31/2025 |
4 | 43 Bn Airborne ISR Markets, 2020-2025, 2025-2030F, 2035F - Growing Counterterrorism Efforts and Geopolitical Tensions Further Drive Market Growth | 01/09/2026 |
5 | Perspective Therapeutics Buy Rating Reiterated at BTIG Research - MarketBeat | 01/13/2026 |
6 | A Look At Perspective Therapeutics Valuation After New VMT--NET Trial And Pipeline Updates | 02/02/2026 |
7 | Comparing Perspective Therapeutics Its Rivals | 02/13/2026 |
| Begin Period Cash Flow | 9.4 M | |
| Total Cashflows From Investing Activities | -218.9 M |
Perspective | Build AI portfolio with Perspective Stock |
Perspective Therapeutics Relative Risk vs. Return Landscape
If you would invest 221.00 in Perspective Therapeutics on November 16, 2025 and sell it today you would earn a total of 249.00 from holding Perspective Therapeutics or generate 112.67% return on investment over 90 days. Perspective Therapeutics is currently generating 1.6927% in daily expected returns and assumes 10.6946% risk (volatility on return distribution) over the 90 days horizon. In different words, 96% of stocks are less volatile than Perspective, and 66% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Perspective Therapeutics Target Price Odds to finish over Current Price
The tendency of Perspective Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 4.70 | 90 days | 4.70 | roughly 2.58 |
Based on a normal probability distribution, the odds of Perspective Therapeutics to move above the current price in 90 days from now is roughly 2.58 (This Perspective Therapeutics probability density function shows the probability of Perspective Stock to fall within a particular range of prices over 90 days) .
Perspective Therapeutics Price Density |
| Price |
Predictive Modules for Perspective Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Perspective Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Perspective Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Perspective Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Perspective Therapeutics is not an exception. The market had few large corrections towards the Perspective Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Perspective Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Perspective Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 1.47 | |
β | Beta against Dow Jones | 1.32 | |
σ | Overall volatility | 0.92 | |
Ir | Information ratio | 0.14 |
Perspective Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Perspective Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Perspective Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Perspective Therapeutics is way too risky over 90 days horizon | |
| Perspective Therapeutics appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (79.28 M) with loss before overhead, payroll, taxes, and interest of (60.89 M). | |
| Perspective Therapeutics generates negative cash flow from operations | |
| About 58.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from thelincolnianonline.com: Comparing Perspective Therapeutics Its Rivals |
Perspective Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Perspective Stock often depends not only on the future outlook of the current and potential Perspective Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Perspective Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 64.4 M | |
| Cash And Short Term Investments | 226.9 M |
Perspective Therapeutics Fundamentals Growth
Perspective Stock prices reflect investors' perceptions of the future prospects and financial health of Perspective Therapeutics, and Perspective Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Perspective Stock performance.
| Return On Equity | -0.37 | ||||
| Return On Asset | -0.17 | ||||
| Operating Margin | (133.31) % | ||||
| Current Valuation | 401.02 M | ||||
| Shares Outstanding | 113.91 M | ||||
| Price To Book | 2.36 X | ||||
| Price To Sales | 531.95 X | ||||
| Gross Profit | (60.89 M) | ||||
| EBITDA | 10.46 M | ||||
| Net Income | (79.28 M) | ||||
| Total Debt | 4.06 M | ||||
| Book Value Per Share | 3.26 X | ||||
| Cash Flow From Operations | (18.29 M) | ||||
| Earnings Per Share | (1.51) X | ||||
| Market Capitalization | 571.85 M | ||||
| Total Asset | 341.1 M | ||||
| Retained Earnings | (231.72 M) | ||||
| Working Capital | 212.93 M | ||||
About Perspective Therapeutics Performance
Evaluating Perspective Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Perspective Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Perspective Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 84.62 | 88.85 | |
| Return On Tangible Assets | (0.31) | (0.30) | |
| Return On Capital Employed | 0.04 | 0.04 | |
| Return On Assets | (0.27) | (0.25) | |
| Return On Equity | (0.31) | (0.33) |
Things to note about Perspective Therapeutics performance evaluation
Checking the ongoing alerts about Perspective Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Perspective Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Perspective Therapeutics is way too risky over 90 days horizon | |
| Perspective Therapeutics appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (79.28 M) with loss before overhead, payroll, taxes, and interest of (60.89 M). | |
| Perspective Therapeutics generates negative cash flow from operations | |
| About 58.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from thelincolnianonline.com: Comparing Perspective Therapeutics Its Rivals |
- Analyzing Perspective Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Perspective Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Perspective Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Perspective Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Perspective Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Perspective Therapeutics' stock. These opinions can provide insight into Perspective Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Perspective Stock Analysis
When running Perspective Therapeutics' price analysis, check to measure Perspective Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Perspective Therapeutics is operating at the current time. Most of Perspective Therapeutics' value examination focuses on studying past and present price action to predict the probability of Perspective Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Perspective Therapeutics' price. Additionally, you may evaluate how the addition of Perspective Therapeutics to your portfolios can decrease your overall portfolio volatility.